Fabrazyme - supply shortage

Resolved

agalsidase beta

Shortage information

The shortage affecting Fabrazyme has been resolved and the information and recommendations which were issued during the shortage no longer apply.

Key facts

• Medicines affected:
  Fabrazyme
• Supply shortage status:
  Resolved
• International non-proprietary name (INN) or common name:
  agalsidase beta
• Therapeutic area (MESH):
  Fabry Disease
• Pharmaceutical forms affected:
  Powder for concentrate for solution for infusion
• Strengths affected:
  • 5 mg
  • 35 mg
• Availability of alternatives:
  No

Key dates

• First published:
  04/11/2013
• Last updated:
  07/06/2016